arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Sight Sciences, Inc.

SGHT
$7.49 ▲ +0.40 (+5.64%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
7 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sight Sciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $390.6M
Dividend Yield
Revenue Growth -3.1%
Op. Margin -48.0%
ROIC -34.9%
FCF / Share $-0.57
Trailing P/E
Price / Book 6.3x
FCF Yield
Debt / Equity 0.66
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.36M
↓ -3.1%
Net Income Profit after all expenses
$-38.43M
↑ +25.4%
Operating Margin Operating profit as % of sales
-48.0%
↑ +24.2% 5th
FCF / Share Free cash flow per share
$-0.57
↓ -26.5%
Long-Term Debt Long-term obligations
$42.38M
↑ +5.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
14
Financial Health
38
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters